Resistance to insulin leads to type 2 diabetes mellitus (T2DM) but only when accompanied by pancreatic β-cell dysfunction. This Review describes the molecular mechanisms associated with pancreatic β-cell dysfunction in T2DM and discusses how modulating FOXO1 activity might serve as a new therapeutic target to treat T2DM.